What it is
A long-acting dual GIP and GLP-1 receptor agonist administered as a once-weekly subcutaneous injection.
How it works
Simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing food intake.
Where it's used
Used in type 2 diabetes (Mounjaro), chronic weight management (Zepbound), and moderate-to-severe obstructive sleep apnea with obesity (Zepbound).
FDA-approved use
Type 2 diabetes (Mounjaro); chronic weight management and obstructive sleep apnea in adults with obesity (Zepbound).
Tracking it
Tirzepatide is injectable, so two things matter in a log: when you dosed and where. Rotating sites and writing both down prevents the classic “did I already pin the left side?” problem. with a half-life of about 5 days (120 h), a dose log also lets a tracker model the relative amount still in your system between doses. for titrated compounds like this one, a log that records the dose at each step is the difference between knowing your history and guessing it.
Source
OpenFDA
Last reviewed 2026-06-11